Biomarkers in alzheimer's disease;Biomarcadores en la enfermedad de Alzheimer

Revista de Neurologia

Volumn 58, Issue 7, 2014, Pages 308-317

  García Ribas, Guillermo ^a   López Sendón Moreno, José Luis ^a   García Caldentey, Juan ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Alzheimer's disease; Amyloid beta; Biomarkers; Cerebrospinal fluid; Phosphorylated tau; Review; Total tau

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; PHARMACOLOGICAL BIOMARKER; PHOSPHORYLATED TAU PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG; APOLIPOPROTEIN E4; MAPT PROTEIN, HUMAN; PRESENILIN 1; PSEN1 PROTEIN, HUMAN;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID; DEMENTIA; DISEASE COURSE; DISEASE MARKER; FUNCTIONAL NEUROIMAGING; HUMAN; MILD COGNITIVE IMPAIRMENT; NEUROPATHOLOGY; REVIEW; BLOOD; CHEMISTRY; COGNITION DISORDERS; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; GENETIC PREDISPOSITION; GENETICS; PREDICTIVE VALUE; ANALYTIC METHOD; ARTICLE; BLOOD ANALYSIS; CLINICAL TRIAL (TOPIC); DISEASE CLASSIFICATION; GENE MUTATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEIN E4; BIOLOGICAL MARKERS; COGNITION DISORDERS; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; EARLY DIAGNOSIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MILD COGNITIVE IMPAIRMENT; PREDICTIVE VALUE OF TESTS; PRESENILIN-1; TAU PROTEINS;

EID: 84897560492     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5807.2013394     Document Type: Review

References (129)

1. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1143-53.
2. Molinuevo JL, Peña-Casanova J, eds. Guía oficial para la práctica clínica en demencias: conceptos, criterios y recomendaciones 2009. SEN. Barcelona: Thomson-Reuters; 2009.
3. Erkinjuntti T, Ostbye T, Steenhuis R, Hachinski V. The effect of different diagnostic criteria on the prevalence of dementia. N Engl J Med 1997; 337: 1667-74.
4. Sawa GM, Wharton SB, Lince PG, Forster G, Matthews FE, Brayne C; Medical Research Council Cognitive Function and Ageing Study. Age, neuropathology, and dementia. N Engl J Med 2009; 360: 2302-9.
5. Real Academia Española. Alzheimer [artículo enmendado]. Diccionario de la lengua española (23.a ed.) URL: http://buscon.rae.es//draeI/SrvltConsulta?TIPO_BUS=3&LEMA=alzheimer.
6. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 1984; 34: 939-44.
7. Beach TG, Monsell SE, Phillips LE, Kukull WE. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer's Disease Centers, 2005-2010. J Neuropathol Exp Neurol 2012; 71: 266-73.
8. Hogervorst E, Barneston L, Jobst KA, Nagy Z, Combrinck M, Smith AD. Diagnosing dementia: interrater reability assessment and accuracy of the NINCDS/ADRDA criteria versus CERAD histopathological criteria for Alzheimer's disease. Dement Geriatr Cogn Disord 2000; 11: 107-13.
9. Bowler JV, Muñoz DG, Merskey H, Hachinski V. Fallacies in the pathological confirmation of the diagnosis of Alzheimer's disease. J Neurol Neurosurg Psychiatry 1998; 64: 18-24.
10. Karantzoulis S, Galvin JE. Distinguishing Alzheimer's disease from other major forms of dementia. Expert Rev Neurother 2011; 11: 1579-91.
11. Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 1997; 56: 1095-7.
12. Morris JC, Price AL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci 2001; 17: 101-18.
13. Crystal H, Dickson D, Fuld P, Masur D, Scott R, Mehler M, et al. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 1998; 38: 1682-7.
14. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 2012; 71: 362-81.
15. Lleó A, Berezovska O, Growdon JH, Hyman BT. Clinical, pathological, and biochemical spectrum of Alzheimer disease associated with PS-1 mutations. Am J Geriatr Psychiatry 2004; 12: 146-56.
16. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012; 8: 1-13.
17. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairos NJ, Dickson DW, et al; National Institute on Aging; Alzheimer's Association. National Institute of Aging-Alzheimer's Association guidelines for the neuropathological assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 2012; 123: 1-11.
18. McKeith I, Cummings J. Behavioural changes and psychological symptoms in dementia disorders. Lancet Neurol 2005; 4: 735-42.
19. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001; 58: 1985-92.
20. Hampel H, Bürger K, Teipel SJ, Bokde Al, Zetterberg H, Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement 2008; 4: 38-48.
21. Cummings JL, Dubois B, Molinuevo JL, Scheltens P. International Work Group Criteria for the diagnosis of Alzheimer disease. Med Clin N Am 2013; 97: 363-8.
22. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263-9.
23. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 270-9.
24. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280-92.
25. Lazarczyk MJ, Hof PR, Bouras C, Giannakopoulos P. Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals. BMC Med 2012; 10: 127.
26. Sperling RA, Karlawish J, Johnson KA. Preclinical Alzheimer disease-the challenges ahead. Nat Rev Neurol 2013; 9: 54-8.
27. Rosén C, Hansson O, Blennow K, Zetterberg H. Fluid biomarkers in Alzheimer's disease -current concepts. Mol Neurodegener 2013; 8: 20.
28. Mattsson N, Zegers I, Andreasson U, Bjerke M, Blankenstein MA, Bowser R, et al. Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42. Biomark Med 2012; 6: 409-17.
29. Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology 2007; 68: 666-9.
30. Palmert MR, Usiak M, Mayeux R, Raskind M, Tourtellotte WW, Younkin SG. Soluble derivatives of the β amyloid protein precursor in cerebrospinal fluid: alterations in normal aging and in Alzheimer's disease. Neurology 1990; 40: 1028-32.
31. Strozyk D, Blennow K, White LR, Launer LJ. CSF Abeta 42 levels correlate with amyloid-neuropathology in a populationbased autopsy study. Neurology 2003; 60: 652-6.
32. Engelborghs S, De Vreese K, Van de Casteele T, Vanderstichele H, Van Everbroeck B, Cras P, et al. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging 2008; 29: 1143-59.
33. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, et al. Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009; 66: 382-9.
34. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006; 59: 512-9.
35. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008; 29: 1456-65.
36. Grimmer T, Riemenschneider M, Forstl H, Henriksen G, Klunk WE, Mathis CA, et al. Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 2009; 65: 927-34.
37. Shoji M. Cerebrospinal fluid Abeta40 and Abeta42: natural course and clinical usefulness. Front Biosci 2002; 7: d997-1006.
38. Fukuyama R, Mizuno T, Mori S, Nakajima K, Fushiki S, Yanagisawa K. Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from controls subjects, and a decrease in the ratio of Abeta42 to Abeta40 levels in cerebrospinal fluid from Alzheimer's disease patients. Eur Neurol 2000; 43: 155-60.
39. Franz G, Beer R, Kampfl A, Engelhardt K, Schmutzhard E. Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury. Neurology 2003; 60: 1457-61.
40. Tsitsopoulos PP, Marklund N. Amyloid-β peptides and tau protein as biomarkers in cerebrospinal and interstitial fluid following traumatic brain injury: a review of experimental and clinical studies. Front Neurol 2013; 4: 79.
41. Trysberg E, Höglund K, Svenungsson E, Blennow K, Tarkowski A. Decreased levels of soluble amyloid β-protein precursor and β-amyloid protein in cerebrospinal fluid of patients with systemic lupus erythematosus. Arthritis Res Ther 2004; 6: R129-36.
42. Perucho J, Rubio I, Casarejos MJ, Gómez A, Rodríguez-Navarro JA, Solano RM, et al. Anesthesia with isofluorane increases amyloid pathology in mice models of Alzheimer's disease. J Alzheimers Dis 2010; 19: 1245-57.
43. Papon MA, Whittington RA, El-Khoury NB, Planel E. Alzheimer's disease and anesthesia. Front Neurosci 2011; 4: 272.
44. Clifford DB, Fagan AM, Holtzman DM, Morris JC, Teshome M, Shah AR, et al. CSF biomarkers of Alzheimer disease in HIVassociated neurologic disease. Neurology 2000; 73: 1982-7.
45. Holmberg B, Johnels B, Blennow K, Rosengren L. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Mov Disord 2003; 18: 186-90.
46. Renard D, Castelnovo G, Wacongne A, Le Floch A, Thouvenot E, Mas J, et al. Interest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteria. J Neurol 2012; 259: 2429-33.
47. Formichi P, Parnetti L, Radi E, Cevenini G, Dotti MT, Federico A. CSF biomarkers profile in CADASIL. A model of pure vascular dementia: usefulness in differential diagnosis in the dementia disorder. Int J Alzheimers Dis 2010; 2010: doi:10.4061/2010/959257.
48. Mulder C, Verwey NA, Van der Flier WM, Bouwman FH, Kok A, Van Elk EJ, et al. Amyloid-beta (1-42), total tau, and phosphorilated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem 2010; 56: 248-53.
49. El Mouedden M, Vandermeeren M, Meert T, Mercken M. Development of a specific ELISA for the quantitative study of amino-terminally truncated beta-amyloid peptides. J Neurosci Methods 2005; 145: 97-105.
50. Portelius E, Mattson N, Andreasson U, Blennow K, Zetterberg H. Novel Aβ isoforms in Alzheimer's disease: their role in diagnosis and treatment. Curr Pharm Des 2011; 17: 2594-602.
51. Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci 2003; 23: 8844-53.
52. Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, et al. The Alzheimer's association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 2011; 7: 386-95.
53. Carrillo MC, Blennow K, Soares H, Lewczuk P, Mattsson N, Oberoi P, et al. Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: an update from the Alzheimer's association global biomarkers consortium. Alzheimers Dement 2013; 9: 137-40.
54. Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K, et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol 2011; 121: 597-609.
55. Jensen M, Asun H, Lannfelt L. Increased cerebrospinal fluid tau in patients with Alzheimer's disease. Neurosci Lett 1995; 186: 189-91.
56. Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H, Trojanowski JQ. Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol 2010; 45: 30-40.
57. Hesse C, Rosengren L, Andreasen N, Davidsson P, Vanderstichele H, Vanmechelen E, et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett 2001; 297: 187-90.
58. Gómez-Tortosa E, Gonzalo I, Fanjul S, Sainz MJ, Cantarero S, Cemillán C, et al. Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease. Arch Neurol 2003; 60: 1218-22.
59. Wang GR, Gao C, Shi Q, Zhou W, Chen JM, Dong CF, et al. Elevated levels of tau protein in cerebrospinal fluid of patients with probable Creutzfeldt-Jakob disease. Am J Med Sci 2010; 340: 291-5.
60. Skoog I, Davidsson P, Aevarsson O, Vanderstichele H, Vanmechelen E, Blennow K. Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord 2003; 15: 169-76.
61. Reiman EM, Quiroz YT, Fleisher AS, Chen K, Vélez-Pardo C, Jiménez-Del-Río M, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol 2012; 11: 1048-56.
62. Andersson M, Zetterberg H, Minthon LL, Blennow K, Londos E. The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia. Int J Geriatr Psychiatry 2011; 26: 100-5.
63. Irwin DJ, Trojanowski JQ, Grossman M. Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease. Front Aging Neurosci 2013; 5: 6.
64. Buerger K, Zinkowski R, Teipel SJ, Aral H, DeBernardis J, Kerkman D, et al. Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorilated at threonine 231. Am J Psychiatry 2003; 160: 376-9.
65. Agren-Wilsson A, Lekman A, Sjoberg W, Rosengren AT, Blennow K, Bergenheim AT, et al. CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus. Acta Neurol Scand 2007; 116: 333-9.
66. Zetterberg H, Jonson M, Rasulzada A, Popa C, Styrud E. No neurochemical evidence for brain injury causing by heading in soccer. Br J Sports Med 2007; 41: 574-7.
67. Neselius S, Brisby H, Theodorsson AA, Blennow K, Zetterber H, Marcusson J. CSF-biomarkers in Olympic boxing: diagnosis and effects of repetitive head trauma. PLoS One 2012; 7: e33606.
68. Glodzik-Sobanska L, Pirraglia E, Brys M, De Santi S, Mosconi L, Rich KE, et al. The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease. Neurobiol Aging 2009; 30: 672-81.
69. Kester MI, Scheffer PG, Koel-Simmelink MJ, Twaalfhoven H, Verwey NNA, Veerhuis R, et al. Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers. Neurobiol Aging 2012; 33: 1591-8.
70. Monge-Argilés JA, Muñoz-Ruiz C, Sánchez-Payá J, Montoya-Gutiérrez FJ, Borja E, Leiva-Santana C. Biomarcadores en el líquido cefalorraquídeo de pacientes con enfermedad de Alzheimer prodrómica. Alzheimer Real Invest Demenc 2011; 49: 19-25.
71. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem 1995; 26: 231-45.
72. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van der Perre B, Sjögren M, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000; 285: 49-52.
73. Kohnken R, Buerger K, Zinkowski R, Miller C, Kerkman D, DeBernardis J, et al. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett. 2000; 287: 187-90.
74. Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, et al. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 2005; 51: 336-45.
75. Mattsson N, Rosen E, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology 2012; 78: 468-76.
76. Samgard K, Zetterberg H, Blennow K, Hansson O, Minthon L, Londos E. Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity. Int J Geriatr Psychiatry 2010; 25: 403-10.
77. Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O. CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology 2010; 74: 1531-7.
78. Van Rossum IA, Vos SJ, Burns L, Knol DL, Scheltens P, Soininen H, et al. Injury markers predict time to dementia in subjects with MCI and amyloid pathology. Neurology 2012; 79: 1809-16.
79. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009; 302: 385-93.
80. Molinuevo JL, Gispert JD, Pujol J, Rojas S, Lladó A, Balasa M, et al. Una nueva aproximación en el diagnóstico de la enfermedad de Alzheimer con biomarcadores: descripción del AD-CSF-Index. Rev Neurol 2012; 54: 513-22.
81. Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, Aggarwal NT, et al. Natural history of mild cognitive impairment in older persons. Neurology 2002; 59: 198-205.
82. Mufson EJ, Binder L, Counts SE, DeKosky ST, De Toledo-Morrell L, Ginsberg SD, et al. Mild cognitive impairment: pathology and mechanisms. Acta Neuropathol 2012; 123: 13-30.
83. Monge-Argilés JA, Sánchez-Payá J, Muñoz-Ruiz C, Pampliega-Pérez A, Montoya-Gutiérrez J, Leiva-Santana C. Biomarcadores en el líquido cefalorraquídeo de pacientes con deterioro cognitivo leve: metanálisis de su capacidad predictiva para el diagnóstico de la enfermedad de Alzheimer. Rev Neurol 2010; 50: 193-200.
84. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 228-34.
85. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012; 69: 98-106.
86. Palmqvist S, Hertze J, Minthon L, Wattmo C, Zetterberg H, Blennow K, et al. Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer's disease in mild cognitive impairment: six-year follow-up study. PLoS One 2012; 7: e38639.
87. Richard E, Schmad BA, Eikelenboom P, Van Gool WA, The Alzheimer's Disease Neuroimaging Initiative. MRI and cerebrospinal fluid biomarkers for predicting progression to Alzheimer's disease in patients with mild cognitive impairment: a diagnostic accuracy study. BMJ Open 2013; 3: e002541.
88. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012; 367: 795-804.
89. Van Harten AC, Visser PJ, Pijnenburg YA, Teunissen CE, Blankenstein MA, Scheltens P, et al. Cerebrospinal fluid Abeta42 is the best predictor of clinical progression in patients with subjective complaints. Alzheimers Dement 2013; 9: 481-7.
90. Schott JM, Bartlett JW, Fox NC, Barnes J. Alzheimer's disease neuroimaging initiative: increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Abeta1-42. Ann Neurol 2010; 68: 825-34.
91. Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013; 12: 207-16.
92. Buchhave P, Blennow K, Zetterberg H, Stomrud E, Londos E, Andreasen N, et al. Longitudinal study of CSF biomarkers in patients with Alzheimer's disease. PLoS One 2009; 4: e6294.
93. Guzmán-Martínez L, Farías GA, Maccioni RB. Emerging noninvasive biomarkers for early detection of Alzheimer's disease. Arch Med Res 2012; 43: 663-6.
94. Bettens K, Sleegers K, Van Broeckhoven C. Genetic insights in Alzheimer's disease. Lancet Neurol 2013; 12: 92-104.
95. Briones N, Dinu V. Data mining of high density genomic variant data for prediction of Alzheimer's disease risk. BMC Med Genet 2012; 13: 7.
96. Britschgi M, Rufibach K, Huang SL, Clark CM, Kaye JA, Li GB, et al. Modeling of pathological traits in Alzheimer's disease based on systemic extracellular signalling proteome. Mol Cell Proteomics 2011; 10: M111.008862.
97. Wang Y, Sørensen MG, Zheng Q, Zhang C, Karsdal MA, Henriksen K. Will posttranslational modification of brain proteins provide novel serological markers for dementias? Int J Alzheimer Dis 2012; 2012: 209409.
98. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 2000; 57: 100-105.
99. Bush AI, Beyereuther K, Masters CL. The beta A4 amyloid protein precursor in human circulation. Ann NY Acad Sci 1993; 695: 175-82.
100. Mandelkow EM, Mandelkow E. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med 2012; 2: a006247.
101. Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, et al. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging 2010; 31: 357-67.
102. Lopez OL, Kuller LH, Mehta PD, Becker JT, Gach HM, Sweet RA, et al. Plasma amyloid levels and the risk of AD in normal subjects in the cardiovascular health study. Neurology 2008; 70: 1664-71.
103. Van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 2006; 5: 655-60.
104. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, et al. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 2007; 64: 354-62.
105. Yaffé K, Weston A, Graff-Radford NR, Satterfield S, Simonsick EM, Younkin SG, et al. Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 2011; 305: 261-6.
106. Pesini P, Pérez-Grijalba V, Monleón I, Boada M, Tárraga L, Martínez-Lage P, et al. Reliable measurements of the β-amyloid pools in blood could help in early diagnosis of AD. Int J Alzheimers Dis 2012; 2012: 604141.
107. Koyama A, Okereke OI, Yang T, Blacker D, Selkoe DJ, Grodstein F. Plasma amyloid-beta as a predictor of dementia and cognitive decline: a systematic review and meta-analysis. Arch Neurol 2012; 69: 824-31.
108. Velayudhan L, Killick R, Hye A, Kinsey A, Guntert A, Lynham S, et al. Plasma transthyretin as a candidate marker for Alzheimer's disease. J Alzheimers Dis 2012; 28: 369-75.
109. Sato Y, Suzuki I, Nakamura T, Bernier F, Aoshima K, Oda Y. Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology. J Lipid Res 2012; 53: 567-76.
110. Lim NK, Villemagne VL, Soon CP, Laughton KM, Rowe CC, McLean CA, et al. Investigation of matrix metalloproteinases, MMP-2 and MMP-9, in plasma reveals a decrease of MMP-2 in Alzheimer's disease. J Alzheimers Dis 2011; 26: 779-86.
111. Choi J, Lee HW, Suk K. Plasma level of chitinase 3-like 1 protein increases in patients with early Alzheimer's disease. J Neurol 2011; 258: 2181-5.
112. Thambisetty M, An Y, Kinsey A, Koka D, Saleem M, Guntert A, et al. Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment. NeuroImage 2012; 59: 212-7.
113. Fagan AM, Perrin RJ. Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. Biomark Med 2012; 6: 455-76.
114. Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP, et al. Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol 2012; 69: 1318-25.
115. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 2007; 13: 1359-62.
116. Bjorkqvist M, Ohlsson M, Minthon L, Hansson O. Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease. PLoS One 2012; 7: e29868.
117. Soares HD, Chen Y, Sabbagh M, Roher A, Schrijvers E, Breteler M. Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels. Ann N Y Acad Sci 2009; 1180: 56-67.
118. Fletcher LC, Burke KE, Caine PL, Rinne NL, Braniff CA, Davis HR, et al. Diagnosing Alzheimer's disease: are we any nearer to useful biomarker-based, non-invasive tests? GMS Health Technol Assess 2013; 9: Doc01.
119. Blennow K, De Meyer G, Hansson O, Minthon L, Wallin A, Zetterberg H, et al. Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment. J Nutr Health Aging 2009; 13: 205-8.
120. Rye PD, Booij BB, Grave G, Lindahl T, Kristiansen L, Andersen HM, et al. A novel blood test for the early detection of Alzheimer's disease. J Alzheimers Dis 2011; 23: 121-9.
121. Fehlbaum-Beurdeley P, Sol O, Désiré L, Touchon J, Dantoine T, Vercelletto M, et al; EHTAD/002 study group. Validation of AclarusDx, a blood-based transcriptomic signature for the diagnosis of Alzheimer's disease. J Alzheimers Dis 2012; 32: 169-81.
122. Goodman JJ. Practical utility of urinary assay in the diagnosis of Alzheimer's disease: AlzheimAlert. Expert Rev Mol Diagn 2008; 8: 21-8.
123. Youn YC, Park KW, Han SH, Kim S. Urine neural thread protein measurements in Alzheimer's disease. J Am Med Dir Assoc 2011; 12: 372-6.
124. Johnstone D, Milward EA, Beretta R, Moscato P; Alzheimer's Disease Neuroimaging Initiative. Multivariate protein signature of pre-clinical Alzheimer's disease in Alzheimer's Disease Neuroimaging Initiative (ADNI) plasma proteome dataset. PLoS One 2012; 7: e34341.
125. Kiddle SJ, Thambisetty M, Simmons A, Riddoch-Contreras J, Hye A. Plasma based markers of [11C] PIB-PET brain amyloid burden. PLoS One 2012; 7: e44260.
126. Johansson P, Mattsson N, Hansson O, Wallin A, Johansson JO, Andreasson U, et al. Cerebrospinal fluid biomarkers for Alzheimer's disease: diagnostic performance in a homogeneous mono-center population. J Alzheimers Dis 2011; 24: 537-46.
127. Mattson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, et al.; Alzheimer's Association QC Program Work Group. CSF Biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement 2013; 9: 251-61.
128. DeFelipe J, Alonso-Nanclares L, Arellano JI. Microstructure of the neocortex: comparative aspects. J Neurocytol 2002; 31: 299-316.
129. Kovacs GG, Milenkovic I, Wöhrer A, Höftberger R, Gelpi E, Haberler C, et al. Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. Acta Neuropathol 2013; 126: 365-84.